Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InSite Vision, Inc.

http://www.insitevision.com

Latest From InSite Vision, Inc.

Finance Watch: The Growing $100m-Plus VC Club

Private Company Edition: Venture capital mega-rounds continue to add up, including recent financings for Connect Biopharma ($115m) and Synthego ($100m). Also, Civilization Ventures closed a new $35m fund and Triumvira launched with $55m.

Financing Innovation

Sun Hopes Cequa’s Nano Formulation Makes Big Impact

Sun’s now-approved higher concentration, quicker-acting formulation of cyclosporine A could offer competitive advantage in dry eye versus Allergan’s Restasis, but is it enough to offset lower costs of pending generic cyclosporines?

Approvals Business Strategies

Pfizer Ex-Marketing Director Agrees To Injunction, Ending Trade Secret Suit

Former Pfizer employee has joined Sun Pharma as it launches ophthalmic drug and expands its specialty portfolio, which includes Phase III monoclonal antibody for treatment of psoriasis.

BioPharmaceutical Policy

First US Branded Ophthalmic Launch A ‘Milestone’ For Sun

India’s biggest drug firm Sun has just launched its first branded ophthalmic product in the US, marking what the company calls “a milestone” in its quest to build scale and seek steady revenue streams in the global specialty drug business.

Launches Ophthalmic
See All

Company Information

UsernamePublicRestriction

Register